

RECEIVED  
CENTRAL FAX CENTER

AUG 22 2005

Attorney Docket No.: 5904.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malmlof et al.

Serial No.: 10/772,997

Group Art Unit: 1654

Filed: February 5, 2004

Examiner: Audet, Maury A.

For: Use of a Growth Hormone or a Growth Hormone Secretagogue for Appetite-Suppression  
or Induction of Satiety

CERTIFICATE OF FACSIMILE TRANSMISSION  
571-273-8300

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
OIPE/IAP

AUG 23 2005

Sir:


I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement (in duplicate)
2. Form PTO-1449
3. One Reference (8 pages)

was sent to the United States Patent and Trademark Office by telefax to the attention of  
Examiner Audet, Maury A. at fax number (571-273-8300).

Respectfully submitted,

Date: August 22, 2005

  
Csaba Attila Szakolczai  
Novo Nordisk® Inc.  
Customer Number 23650  
(609) 987-5800

RECEIVED  
CENTRAL FAX CENTER

AUG 22 2005

Attorney Docket No.: 5904.214-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malmlof et al.

Application No.: 10/772,997

Group Art Unit: 1654

Filed: February 5, 2004

Examiner: Audet, Maury A.

For: Use of a Growth Hormone or a Growth Hormone Secretagogue for Appetite-Suppression or Induction of Satiety

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than that listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. Johannsson et al., Journal of Clinical Endocrinology and Metabolism, Vol. 83 (3), pp. 727-34 (1997)

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of


record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

This supplemental information disclosure statement is being filed **after** the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Date: August 22, 2005

Respectfully Submitted,

  
Den S. Smith, Reg. No. 43,139  
Novo Nordisk® Inc.  
Customer Number 23650  
(609) 987-5800

Use the following customer number for all correspondence regarding this application

**23650**

PATENT TRADEMARK OFFICE

